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Introduction. Type 2 diabetes mellitus (T2DM) is one of the most important obesity-related comorbidities. This study was
undertaken to characterise the eﬀect of the biliopancreatic diversion with duodenal switch (BPD-DS) in morbidly obese and
nonmorbidly obese diabetic patients. Methods. Outcome of 74 obese diabetic patients after BPD-DS and 16 non-obese diabetic
patients after BPD or gastric bypass surgery was evaluated. Insulin usage, HbA1c-levels, and index of HOMA-IR (homeostasis
model assessment of insulin resistence) were measured. Results. A substantial fraction of patients is free of insulin and shows an
improved insulin sensitivity early after the operation, another fraction gets free of insulin in a 12-month period after the operation
andasmallfractionoflong-terminsulinuserswillnotgetfreeofinsulinbutneverthelessshowsanimprovedmetabolicstatus(less
insulin needed, normal HbA1c-levels). Conclusion. BPD-DS leads to an improvement of T2DM in obese and non-obese patients.
Nevertheless, more data is needed to clarify indications and mechanisms of action and to adjust our operation techniques to the
needs of non-obese diabetic patients.
1.Introduction
Obese patients’ lifetime and life quality are not only limited
by obesity itself but also by associated disorders, in particular
type 2 diabetes mellitus (T2DM). Patients need medication,
regular subcutaneous injections, and should keep a diet.
Frequently, the diabetes is poorly controlled, which leads
to various complications, even failure of organs. Serious
vascular diseases may occur, and some patients need dialysis
or surgery because of diabetes related complications. For-
tunately bariatric surgery shows eﬀects not only on body
weight but also on glucose homoeostasis. In the long-term
some operations show better results concerning diabetes
than concerning weight loss. Patients remain overweight but
experience remission from diabetes [1]. The question arises
if we should rather talk of “diabetes surgery” than “bariatric
surgery” when operating an obese patient with T2DM [2].
Thenextstepwouldconsequentlybethe“antidiabetic”oper-
ation of non-obese patients with inadequately controlled
diabetes [3–5]. The “Standards of Medical Care in Diabetes”
published yearly by the American Diabetes Association, for
the ﬁrst time, mentions surgical therapy in 2009 [6]. They
recommend bariatric surgery for adults with BMI >35kg/m2
and type 2 diabetes, especially if the diabetes or associated
comorbidities are diﬃcult to control with lifestyle and phar-
macologic therapy. However, theystate that thereis currently
insuﬃcient evidence to generally recommend surgery in
patients with BMI <35kg/m2 outside of a research protocol.
These recommendations were assumed without any change
for 2010 [7]. Similar recommendations were made by
the Diabetes Surgery Summit Consensus Conference in
2010: surgery should be considered for patients with BMI
>35kg/m2 who are inadequately controlled by lifestyle and
medicaltherapy.Asurgicalapproachmayalsobeappropriate
as an nonprimary alternative to treat inadequately controlled
diabetes in patients with a BMI of 30–35kg/m2 [8]. The
biliopancreatic diversion with duodenal switch (BPD-DS)
is a well-established bariatric operation with encouraging
eﬀects on glucose homeostasis and diabetes [9, 10]. In
the present study, we present our ﬁrst results concerning
improvement of T2DM in morbidly obese and also in non-
morbidly obese patients. As outcome parameters usage of2 Journal of Obesity
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Figure 1: Reduction of insulin usage prior to BPD-DS, at discharge
and one year after the operation. Blue dots indicate the number
of patients in need of insulin (right scale). Red bars indicate the
mean amount of insulin used per day (left scale, whiskers indicate
standard deviation).
insulin, HbA1c-levels and HOMA-IR index were measured
[11].
2. Patientsand Methods
Patients:asaﬁrstgroup,21obesepatients(9male/12female)
with insulin-dependent T2DM received a biliopancreatic
diversion with duodenal switch (BPD-DS). Mean age was 51
years (26–67), mean preoperative BMI was 46kg/m2 (35–
56), mean duration of diabetes was 10,5 years (2–30), and
preoperative duration of insulin treatment was 6.5 years
(0,5–25) with a mean usage of 98 (25–250) units of insulin
per day. Mean preoperative HbA1c was 9,5% (6,0–14,0).
Body weight, usage of insulin or oral antidiabetic drugs
and HbA1c levels were evaluated 3, 6, and 12 months after
surgery.
Retrospective analysis of sixteen diabetic patients (8
male/8 female) with a BMI <35kg/m2 (mean BMI 32, 26–
34,5) was also performed, mean age was 56 years (36–
68). Mean duration of diabetes was 16 years (4–40), mean
duration of insulin therapy was 6 years (1–12), and mean
daily amount of insulin used was 92IU (30–140). These
patients received either BPD-DS (n = 7), BPD-Scopinaro
(n = 5), or Roux-en-Y gastric bypass (n = 4). All patients
with BMI <35kg/m2 knew that intestinal bypass surgery is
not yet a standard procedure to treat diabetes and signed an
informed consent.
To evaluate early improvements of insulin sensitivity,
HOMA-IRindexwasmeasuredatthedayofsurgeryand3,7,
14, and 21 days after BPD-DS in a group of 27 obese patients
(21patientsusinginsulinbeforesurgery).Meanpreoperative
HOMA-IR index was 14,3.
Seventy-four patients after BPD-DS operations between
February 2005 and January 2009 were retrospectively eval-
uated concerning postoperative outcome in relation to pre-
operative duration of insulin therapy. Mean age was 50 years
(26–68), mean BMI was 47kg/m2. BPD-DS operations were
conducted with a common channel of 100cm in an open
approach. All operations were performed at the Department
of Surgery, St. Josef Hospital Monheim, Germany.
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Figure 2: HbA1c levels prior to BPD-DS and 3, 6, and 12 months
after the operation. Red bars indicate the mean levels of HbA1c,
whiskers indicate standard deviation.
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Figure 3: HOMA index at the day of surgery and 3, 7, 14, and 21
days after BPD-DS (27 patients). Green bars indicate mean HOMA
index (whiskers indicate minimum and maximum values). Seven
days after the operation, the mean HOMA index reaches a normal
value <2.
3. Results
3.1. Remission of Insulin-Dependent Type 2 Diabetes Mellitus
after BPD-DS. In group one, mean preoperative BMI was
46kg/m2 (35–56), mean preoperative duration of insulin
treatment was 6.5 years with a mean usage of 98 units of
insulin per day. At time point of discharge, 15 patients did
not need insulin any more and one year after the operation
insulin therapy was terminated in all patients (Figure 1).
HbA1c levels decreased from preoperatively 9.5 (mean) to 5.9
(mean) and 5.6 (mean) after 6 and 12 months without any
dietary restriction (Figure 2). Only one patient needed an
antidiabeticdrugoneyearaftertheoperation.Inthegroupof
non-obese patients, similar resultswereseen;atdischarge, 13
patientswerefreeofinsulin,and,oneyearaftertheoperation
all patients were free of insulin. Patients after BPD-DS and
BPD-Scopinaro showed slightly better results than patients
after gastric bypass (data not shown).Journal of Obesity 3
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Figure 4: Reduction of insulin usage after BPD-DS dependent on
preoperative duration of insulin usage. Group I “OAD” was treated
by oral antidiabetic drugs only and used no insulin postoperatively.
Group II used insulin for less than 5 years preoperatively and
needed no insulin at discharge and after. Group III used insulin
for 5 to 10 years. Thirty-seven percent of patients in this group
neededinsulinatdischarge(lightbrownbar),butallpatientsinthis
group were free of insulin 1 year after the operation. Group IV used
insulin for more than 10 years. Seventy-three percent of patients in
this group needed insuline at discharge (light brown bar), 23% of
patients in this group still needed insuline 1 year after the operation
(white bar).
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Figure 5: HbA1c levels after BPD-DS dependent on preoperative
duration of insuline usage. Group I “OAD” was treated by oral
antidiabetic drugs only. HbA1c levels were below 6% as early as 3
months after the operation. Group II used insulin for less than 5
years preoperatively and also showed normal levels of HbA1c from
3 months after the operation on. Group III used insulin for 5 to
10 years. Mean HbA1c normalized 6 months after the operation.
Group IV used insulin for more than 10 years. Mean HbA1c in
this group normalized not until 2 years after the operation. Shown
are mean values and additionally minimum/maximum values for
preoperative and 2 years data.
3.2. Decrease of Insulin Resistance in the Early Postoperative
Phase. Mean HOMA-IR index decreased from a preopera-
tivevalueof14.3to3.6,and1.9threeand7daysaftersurgery
(Figure 3). There was no signiﬁcant diﬀerence whether the
patients were treated with oral antidiabetics or with insulin.
Also, three patients who were discharged from hospital with
small amounts of insulin (maximally 36 units per day) had
a low postoperative HOMA-IR index of 1.3 to 2.6. No
dependence of BMI on the postoperative course of insulin
resistance could be detected.
3.3. Inﬂuence of Preoperative Duration of Insulin Therapy on
Postoperative Outcome. According to their need for insulin,
patients in group 3 were divided into 4 groups: 15 patients
were treated with oral antidiabetic medication, 25 used
insulin for less than 5 years, 23 used insulin for 5–10 years,
and 11 used insulin for more than 10 years. At discharge
from hospital, all patients in groups I and II were free of
insulin. Thirty-three percent of patients in group III, still
needed insulin at the time of discharge, but all of them were
free of insulin 12 months after the operation. In group IV,
73%neededinsulinatthetimeofdischarge,23%stillneeded
small amounts of insulin 12 months after the operation
(Figure 4). HbA1c levels also decreased continuously in all
groups. Mean levels below 6% were reached 3 month after
surgery in groups I and II, 6 month after surgery in group III
and 2 years after surgery in group IV (Figure 5).
4. Discussion
In this study, we evaluated short- and long-term eﬀects on
T2DM in patients after BPD-DS. In general, we saw encour-
aging results. This is of major importance since T2DM is
one of the most important obesity-related comorbidities.
Diabetes itself leads to a vast amount of diseases and
complications of diﬀerent organs.
In a group of 21 obese patients with insulin-dependent
T2DM, we evaluated insulin usage and HbA1c levels 6 and 12
months after BPD-DS. These patients had used insulin for
a mean time of 6.5 years, and they had a mean usage of 98
units of insulin per day. Twelve months after the operation,
theywereallfreeofinsulinwithnormalizedHbA1c levelsand
withoutanydietaryrestriction(Figure 2).Mostotherstudies
on BPD/BPD-DS include a substantial fraction of patients
with T2DM who do not need insulin at the time point of
operation but they report similar results, diabetes is resolved
in the majority of cases after 1 year [1, 12]. Remarkably, 15
patients were free of insuline at the time point of discharge,
whereaweightreductionisnotyetachievedand,intheother
patients, a signiﬁcant reduction of insulin doses could be
observed.
In a second collective of patients, the HOMA-IR index
was measured to obtain more information about changes
of insulin sensitivity in the early postoperative phase [12].
HOMA-IR is a product of serum insulin and blood glucose
l e v e la f t e r1 2ho ff a s t i n gw i t hv a l u e s>2 providing evidence
for insulin resistance and levels >5 in patients with T2DM
[11]. We saw that after BPD-DS, the insulin sensitivity
determined by the HOMA-IR index increased rapidly and
usually nearly normalized within few days after surgery. The
restoration of insulin sensitivity was independent on severity
and duration of diabetes and also independent on BMI and
the usage of oral antidiabetic medication.
Finally, to further evaluate whether the remission of
T2DM depends on the duration and severity of diabetes,
74 patients were divided into 4 groups according to their4 Journal of Obesity
need for insulin: we could see that even patients with a long
history of insulin-dependent T2DM have a good chance for
remission. However, in the group with a usage of insulin
>10 years the chance of remission is signiﬁcantly lower
and a small percentage of patients will not be completely
free of insulin—probably due to secondary beta-cell failure.
Nevertheless, HbA1c of these patients is signiﬁcantly lower
and less insulin is required which helps to control diabetes-
associated complications and organ damages. As a summary
of the data, it can be said that a substantial fraction of the
patients is free of insulin and shows an improved insulin
sensitivity early after the operation, another fraction gets free
of insulin in a 12-month period after the operation and a
small fraction of long-term insulin users will not get free of
insulin but nevertheless shows an improved metabolic status
(less insulin needed, normal HbA1c-levels).
The eﬀects of gastrointestinal surgery on glucose
metabolism are not understood in detail. The restrictive
eﬀect of bariatric surgery and the reduced caloric intake
might lead to an improvement of glucose homeostasis and
T2DM in the long run. This eﬀect is equivalent to a diet and
accompanied by weight loss and can be seen after restrictive
operations like gastric banding [13]. A more pronounced
eﬀect can be observed after gastric bypass surgery and BPD
and occurs signiﬁcantly earlier, actually a few days after
surgery, long before a loss of excess weight is achieved.
Other mechanisms beside the “dietary” eﬀect must exist
[14].Intheearlypostoperativeperiod,thosemechanismsare
independentofweightloss,laterontheymightbeadditive to
the dietary-eﬀect which can be seen after restrictive surgery.
The “foregut hypothesis” states that the exclusion of the
duodenum and proximal jejunum from the transient of
nutrients are crucial for this eﬀect, since it has also been seen
in diabetic patients after subtotal gastrectomy due to ulcus
or cancer [15–17]. The neuronal, hormonal, or chemical
signalling pathways which inﬂuence insulin secretion and
glucose homeostasis, and, thus, provide a link between
“foregut” and beta cells are subject of various studies.
The question that consequently arises is the following:
should BPD-DS be performed in non-obese patients with
poorly controlled diabetes? It is not self-evident to expect
that we will observe similar results in non-obese patients,
because obesity itself might change the patients’ metabolic
status and mechanisms of regulation as well as levels and
eﬀects of hormones.
However, we have seen very similar results concerning
usage of insulin and HbA1c in a population of 16 patients
with T2DM and a BMI <35kg/m2. The next important issue
is that the weight-reductive operations, which have been
developed, have an antidiabetic eﬀect but they might not be
the optimal antidiabetic operations in non-obese patients.
Consequently,proceduresmayhavetobeoptimizedfornon-
obese patients with T2DM, resulting in novel antidiabetic
procedures. It has to be determined, for example, if less
gastric restriction—or no gastric restriction, like in case of
the isolated duodenal switch—leads to similar anti-diabetic
results. It has to be found out where to place the distal
anastomosis to obtain optimal anti-diabetic results and
minimal side eﬀects like diarrhea or nutritional deﬁciencies.
As seen in bariatric surgery for morbid obesity, there will
not probably be only a single “anti-diabetic” operation but
several options, depending on the patients’ comorbidities,
weight, and, most likely, also duration and therapy of the
patients’ diabetes.
As a conclusion, we characterized the short- and
medium-term eﬀects of BPD-DS on T2DM. Preliminary
results also show a good anti-diabetic eﬀect in non-morbidly
obese patients. Indications, mechanisms of action, and
developmentofnewsurgicalprocedurestotreatdiabeteswill
be of major interest in the near future.
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